Body composition

BioAdaptives, Inc. Announces NaturaComplete™, an All-In-One Supplement to Optimize Its AI-Based FYO Obesity Management System

Retrieved on: 
Thursday, February 22, 2024

Some dietary methods and the use of certain obesity drugs, like semaglutide, are reported to have unwanted side effects including gastro-intestinal problems like delayed gastric emptying, muscle mass decrease and hair loss.

Key Points: 
  • Some dietary methods and the use of certain obesity drugs, like semaglutide, are reported to have unwanted side effects including gastro-intestinal problems like delayed gastric emptying, muscle mass decrease and hair loss.
  • The ingredients in NaturaComplete™ help to increase the amount of bioavailable nutrients, provide more protein building blocks, stimulate the body’s Primitive cells needed for immune defense and healing, and promote better quality of skin, hair, and nails.
  • This concept has been demonstrated in the highly popular and convenient, One-Stop, Equine All-In-One products, developed by BioAdaptives and shown to have rejuvenating, anti-aging, and performance effects in horses.
  • NaturaComplete™ may be used in conjunction with the AI supported FYO Body Composition smartphone App and can be taken as a meal replacement or as a complementary, additional supplement with any diet.”

InBody Unveils Transformative New Leasing Program, Devices at IHRSA

Retrieved on: 
Wednesday, March 6, 2024

At the IHRSA conference in Los Angeles, medical device pioneer InBody will discuss the biggest financial problem facing health and fitness businesses — technological obsolescence — and unveil their solution for it: a groundbreaking leasing program .

Key Points: 
  • At the IHRSA conference in Los Angeles, medical device pioneer InBody will discuss the biggest financial problem facing health and fitness businesses — technological obsolescence — and unveil their solution for it: a groundbreaking leasing program .
  • View the full release here: https://www.businesswire.com/news/home/20240306774717/en/
    One of InBody's new body composition analyzers, the InBody 580.
  • (Photo: Business Wire)
    “This program makes technological obsolescence itself obsolete,” said Daniel Park, InBody’s Vice President of Sales.
  • The leasing package offers clients access to the latest devices, remote issue monitoring, extensive support and immediate device replacement, as well as a free subscription to LookinBody Web, InBody’s cloud-based data management platform.

Inequalities in the face of cardiovascular risk: women the No. 1 victims

Retrieved on: 
Thursday, March 7, 2024

BOSTON, March 7, 2024 /PRNewswire/ -- Cardiovascular disease kills one women every 33 seconds in the USA10. Yet 80% of these deaths could be avoided11 through early diagnosis and awareness of symptoms and risk factors specific to women. To help reduce this excess mortality, Withings is committed to raising awareness via an exclusive survey, and providing the means to tackle their main cause: hypertension, which accounts for the majority of cardiovascular deaths.12

Key Points: 
  • Inequalities also affect health, particularly cardiovascular health: they lead to under-diagnosis and poorer care for women, resulting in avoidable excess mortality.
  • Yet 80% of these deaths could be avoided11 through early diagnosis and awareness of symptoms and risk factors specific to women.
  • Yet 50% of women are unaware of their cardiovascular risk.13
    45.9% of American women surveyed by Withings admit to putting their loved ones' health before their own.
  • Withings and cardiovascular monitoring in women: the need for a real-life, longitudinal approach
    Monitoring cardiovascular health and hypertension involves tracking a range of biomarkers.

Relive Health Clinic's Grand Opening in East Rutherford, N.J. on February 29th Features Exclusive Promotions on Anti-Aging and Wellness Solutions

Retrieved on: 
Tuesday, February 27, 2024

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Today, Empire Portfolio Group ("Empire") announced the February 29th grand opening celebration of their first Relive Health™ ("Relive") Clinic in East Rutherford, N.J. located at 110 NJ-Route 17.

Key Points: 
  • NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Today, Empire Portfolio Group ("Empire") announced the February 29th grand opening celebration of their first Relive Health™ ("Relive") Clinic in East Rutherford, N.J. located at 110 NJ-Route 17.
  • Relive is a revolutionary anti-aging and wellness franchise that enables individuals to extend their healthspans and enhance their lives by pairing innovative treatments with unparalleled client care.
  • Grand Opening promotional offers that are available from 2/29 – 3/2 include:
    40% off All Single Services – excludes hormone therapy, medical weight loss, bloodwork and packages.
  • To RSVP and learn more about the grand opening specials, visit eastrutherford.relivehealth.com/GrandOpening or follow Relive East Rutherford on Facebook, Instagram, and TikTok.

New Research: Eating Almonds Can Aid in Post-Exercise Recovery

Retrieved on: 
Wednesday, February 21, 2024

MODESTO, Calif., Feb. 21, 2024 /PRNewswire/ -- A new study found that eating almonds reduced some feelings of muscle soreness during exercise recovery which translated to improved muscle performance during a vertical jump challenge. These results expand on prior research1 which looked at how almonds affect muscle recovery after exercise.

Key Points: 
  • These results expand on prior research1 which looked at how almonds affect muscle recovery after exercise.
  • The treadmill test was designed to cause muscle damage to see how almonds affected muscle recovery.
  • Study Conclusion: Snacking on almonds for eight weeks reduced perceived feelings of muscle soreness during recovery from muscle-damaging exercise, resulting in better maintenance of muscle functional capacity.
  • This study suggests that almonds are a functional food snack to improve exercise tolerance in mildly overweight, middle-aged adults.

Dr. Jose Villar Wins 2024 March of Dimes Agnes Higgins Award in Maternal-Fetal Nutrition

Retrieved on: 
Tuesday, February 20, 2024

ARLINGTON, Va., Feb. 20, 2024 /PRNewswire/ -- Dr. Jose Villar, a University of Oxford Professor has been named the 2024 recipient of the March of Dimes Agnes Higgins Award in Maternal-Fetal Nutrition. Dr. Villar, a Professor of Perinatal Medicine at Oxford's Nuffield Department of Women's and Reproductive Health and the former Coordinator of Maternal and Perinatal Health at the World Health Organization (WHO) has spent more than a half century researching the effect of maternal nutrition on the health, growth, and development of babies. The award will be presented to Dr. Villar at the annual meeting of the Pediatric Academic Societies (PAS) on May 4 in Toronto, Canada.

Key Points: 
  • Prominent Oxford scientist led studies on fetal growth, newborn size, and preterm postnatal growth
    ARLINGTON, Va., Feb. 20, 2024 /PRNewswire/ -- Dr. Jose Villar, a University of Oxford Professor has been named the 2024 recipient of the March of Dimes Agnes Higgins Award in Maternal-Fetal Nutrition.
  • The award will be presented to Dr. Villar at the annual meeting of the Pediatric Academic Societies (PAS) on May 4 in Toronto, Canada.
  • They present a universal blueprint for healthy growth and development from early gestation to two years of age.
  • That is the challenge ahead, and I couldn't be prouder to continue it alongside March of Dimes."

Relive Health Clinic's Grand Opening in Metro Atlanta on February 22nd Features Exclusive Promotions on Anti-Aging and Wellness Solutions

Retrieved on: 
Thursday, February 15, 2024

ATLANTA, Feb. 15, 2024 /PRNewswire/ -- Today, Empire Portfolio Group ("Empire") announced the February 22nd grand opening celebration of their first Relive Health™ ("Relive") Clinic in metro Atlanta located at 5001 Peachtree Boulevard, Suite 605 in Chamblee.

Key Points: 
  • ATLANTA, Feb. 15, 2024 /PRNewswire/ -- Today, Empire Portfolio Group ("Empire") announced the February 22nd grand opening celebration of their first Relive Health™ ("Relive") Clinic in metro Atlanta located at 5001 Peachtree Boulevard, Suite 605 in Chamblee.
  • As the first of multiple locations in metro Atlanta, residents can enjoy limited-time, grand opening specials of 40% off individual services and discounts on packaged services.
  • Grand Opening promotional offers include:
    40% off All Single Services – excludes hormone therapy, medical weight loss, bloodwork and packages.
  • To RSVP and learn more about the grand opening specials, visit chamblee.relivehealth.com/GrandOpening or follow Relive Chamblee on Facebook, Instagram, and TikTok.

Reflection paper on investigation of pharmacokinetics in the obese population - Scientific guideline

Retrieved on: 
Wednesday, February 14, 2024

Reflection paper on investigations of pharmacokinetics in

Key Points: 
    • Reflection paper on investigations of pharmacokinetics in
      the obese population
      Table of contents
      1.
    • References .............................................................................................. 9

      Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 2/12

      1.

    • This is considered
      a shortcoming that is potentially compounded by obese patients often being poorly represented in
      clinical studies.
    • The specific aims of this reflection paper are to:
      ?

      describe how the effects of obesity can be investigated during clinical medicinal product
      development.

    • ?

      provide recommendations on when investigations of the effect of obesity on the PK of a
      medicinal product should be particularly considered.

    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 3/12

      ?

      discuss how to reflect PK (and/or PK/PD) findings in weight/weight-based dosing
      recommendations.

    • Absorption
      Reduced rate of absorption linked to locally reduced blood flow (8) is reported for the subcutaneous
      and transdermal routes in obese subjects.
    • Distribution
      The distribution of medicinal products is driven by body composition, regional blood flow and binding to
      tissue and plasma proteins.
    • Obese subjects have a larger absolute lean body weight (LBW) as well as fat mass.
    • The physicochemical properties of a medicinal product (lipophilicity, polarity, molecular size, and
      degree of ionization) influence its distribution in the body.
    • In BMI class III obese
      subjects, the blood flow per gram of fat is significantly lower than that observed in class I obese or
      lean subjects (4).
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 4/12

      An increased amount of alpha-1-acid-glycoprotein (AAG), linked to a chronic inflammatory state, is
      reported in obese individuals.

    • Fatty infiltrations are present in the liver for 90% of obese subjects, with the extent of the infiltrations
      being proportional to the degree of obesity.
    • In some cases, in particular for CYP3A4 metabolized medicinal products,
      bodyweight normalized clearance can be lower in obese patients (23).
    • Based on presently available data, it has been suggested that uptake transporters

      Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 5/12

      are downregulated while efflux transporters may be upregulated (31).

    • Platelet hyper-reactivity is also observed,
      which can impair the response to anti-platelet medicinal products in obese patients (42, 43).
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 6/12

      3.

      the medicinal product properties and scientific literature indicate that obesity may lead to a
      marked effect on elimination and/or distribution or on the PK/PD relationship.

    • These
      models may aid in extrapolating the known efficacy and safety in the non-obese population to the
      obese population.
    • The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients
      Before and One Year After Bariatric Surgery.
    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 11/12

      41.

    • Reflection paper on investigations of pharmacokinetics in the obese population
      EMA/CHMP/535116/2016

      Page 12/12

BioAge Announces $170 Million Oversubscribed Series D Financing to Accelerate Development of Obesity and Metabolic Disease Therapeutics

Retrieved on: 
Tuesday, February 13, 2024

BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, announced today the completion of an oversubscribed Series D financing round of $170 million led by Sofinnova Investments.

Key Points: 
  • BioAge Labs (“BioAge”), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, announced today the completion of an oversubscribed Series D financing round of $170 million led by Sofinnova Investments.
  • In connection with the financing, James Healy, M.D., Ph.D., managing partner at Sofinnova Investments, will join BioAge as Chairman of the Board, and Patrick Enright, managing director at Longitude Capital, will join as Board Director.
  • In preclinical studies, azelaprag doubled the weight loss achieved on incretin drugs with improvements in body composition and muscle function.
  • “We’re thrilled to partner with a top-tier syndicate of investors and pharma companies at the forefront of developing novel therapeutics for metabolic diseases,” said Kristen Fortney, Ph.D., CEO and co-founder of BioAge.

Preamble Debuts as New Membership Longevity Service Harnessing the Three Emerging Trends in Healthcare: Biohacking, Healthspan and Personalized Care

Retrieved on: 
Tuesday, February 6, 2024

Today, Preamble debuts as a healthspan and longevity membership program tackling the phenomenon of medicine 3.0 and the imperative need for a revolution within the healthcare industry.

Key Points: 
  • Today, Preamble debuts as a healthspan and longevity membership program tackling the phenomenon of medicine 3.0 and the imperative need for a revolution within the healthcare industry.
  • The healthspan membership program promises a future where treatments are personalized and technology plays a pivotal role in enhancing patient care.
  • “I founded Preamble with the aim of prioritizing proactive patient care, emphasizing prevention and performance enhancement over merely providing temporary solutions.
  • To join Preamble, membership starts at $2,500 annually with limited availability for founding member spots.